LUND, SWEDEN--(Marketwire - April 29, 2011) -
The number of shares and votes in Active Biotech has changed as a result of the exercise of employee stock options.
Today, the last trading day of the month, there are in total 68,643,420 shares and votes in Active Biotech.
Lund, April 29, 2011
Active Biotech AB (publ)
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn’s and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as RhuDex™ for RA. Please visit www.activebiotech.com for more information.
Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:30 a.m. CET on April 29, 2011.
Number of shares and votes in Active Biotech: http://hugin.info/1002/R/1510260/445247.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1510260]
For further information, please contact:
Hans Kolam
CFO
Tel: +46 (0)46 19 20 44
E-mail: Email Contact
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
